Oryzon Genomics (BME:ORY shareholders incur further losses as stock declines 11% this week, taking five-year losses to 39%

By
Simply Wall St
Published
December 07, 2021
BME:ORY
Source: Shutterstock

Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both over-performing and under-performing stocks. At this point some shareholders may be questioning their investment in Oryzon Genomics S.A. (BME:ORY), since the last five years saw the share price fall 39%. Furthermore, it's down 20% in about a quarter. That's not much fun for holders.

If the past week is anything to go by, investor sentiment for Oryzon Genomics isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

View our latest analysis for Oryzon Genomics

Because Oryzon Genomics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last half decade, Oryzon Genomics saw its revenue increase by 18% per year. That's better than most loss-making companies. Shareholders are no doubt disappointed with the loss of 7%, each year, in that time. You could say that the market has been harsh, given the top line growth. So now is probably an apt time to look closer at the stock, if you think it has potential.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
BME:ORY Earnings and Revenue Growth December 7th 2021

If you are thinking of buying or selling Oryzon Genomics stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

Oryzon Genomics shareholders are down 1.3% for the year, but the market itself is up 5.1%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, longer term shareholders are suffering worse, given the loss of 7% doled out over the last five years. We'd need to see some sustained improvements in the key metrics before we could muster much enthusiasm. It's always interesting to track share price performance over the longer term. But to understand Oryzon Genomics better, we need to consider many other factors. Even so, be aware that Oryzon Genomics is showing 3 warning signs in our investment analysis , and 1 of those is concerning...

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on ES exchanges.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.